相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Early Aggressive Treatment Approaches for Multiple Sclerosis
Alexandra Simpson et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2021)
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis
Kelly R. Cotchett et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
Anna Jamroz-Wisniewska et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis
Paolo Preziosa et al.
NEUROTHERAPEUTICS (2020)
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Finn Sellebjerg et al.
CNS DRUGS (2020)
Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab-functional implication towards PML risk
Marina Kleopatra Boziki et al.
NEUROLOGICAL RESEARCH (2020)
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
James Bowen et al.
ADVANCES IN THERAPY (2020)
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
David Baker et al.
FRONTIERS IN IMMUNOLOGY (2020)
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Helmut Butzkueven et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Highly active multiple sclerosis: An update
Cindy Diaz et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study
Erica Curti et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Pulsed immune reconstitution therapy in multiple sclerosis
Per Soelberg Sorensen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Cladribine: mechanisms and mysteries in multiple sclerosis
Benjamin Meir Jacobs et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Johannes Lorscheider et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Johannes Lorscheider et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Real-life clinical use of natalizumab and fingolimod in Austria
M. Guger et al.
ACTA NEUROLOGICA SCANDINAVICA (2018)
A longitudinal real-life comparison study of natalizumab and fingolimod
R. Lanzillo et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod
Nils Koch-Henriksen et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod
Nils Koch-Henriksen et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study
S. Licata et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Pei-Ran Ho et al.
LANCET NEUROLOGY (2017)
Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
Eline Huisman et al.
BMJ OPEN (2017)
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Jeffrey A. Cohen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
Damiano Baroncini et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Comparative efficacy of fingolimod vs natalizumab A French multicenter observational study
Laetitia Barbin et al.
NEUROLOGY (2016)
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
Damiano Baroncini et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials
Georgios Tsivgoulis et al.
PLOS ONE (2016)
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Tomas Kalincik et al.
ANNALS OF NEUROLOGY (2015)
Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study
Alberto Gajofatto et al.
EUROPEAN NEUROLOGY (2014)
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy
Robert L. Carruthers et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Per Soelberg Sorensen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
分享论文
